# Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

> **NCT01029054** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 53 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** carfilzomib, lenalidomide plus dexamethasone
- **DRUG:** carfilzomib, lenalidomide plus dexamethasone

## Key facts

- **NCT ID:** NCT01029054
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-12
- **Final completion:** 2015-07
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2017-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01029054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01029054, "Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01029054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*